首页|Glucagon-like peptide-1 receptor:mechanisms and advances in therapy
Glucagon-like peptide-1 receptor:mechanisms and advances in therapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
The glucagon-like peptide-1(GLP-1)receptor,known as GLP-1R,is a vital component of the G protein-coupled receptor(GPCR)family and is found primarily on the surfaces of various cell types within the human body.This receptor specifically interacts with GLP-1,a key hormone that plays an integral role in regulating blood glucose levels,lipid metabolism,and several other crucial biological functions.In recent years,GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms,significant therapeutic efficacy,and broad development prospects.This article thoroughly traces the developmental milestones of GLP-1 drugs,from their initial discovery to their clinical application,detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties.Additionally,this paper explores the potential applications of GLP-1 receptor agonists(GLP-1 RAs)in fields such as neuroprotection,anti-infection measures,the reduction of various types of inflammation,and the enhancement of cardiovascular function.It provides an in-depth assessment of the effectiveness of GLP-1 RAs across multiple body systems-including the nervous,cardiovascular,musculoskeletal,and digestive systems.This includes integrating the latest clinical trial data and delving into potential signaling pathways and pharmacological mechanisms.The primary goal of this article is to emphasize the extensive benefits of using GLP-1 RAs in treating a broad spectrum of diseases,such as obesity,cardiovascular diseases,non-alcoholic fatty liver disease(NAFLD),neurodegenerative diseases,musculoskeletal inflammation,and various forms of cancer.The ongoing development of new indications for GLP-1 drugs offers promising prospects for further expanding therapeutic interventions,showcasing their significant potential in the medical field.
Department of Orthopaedics,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200233,China
Institute of Microsurgery on Extremities,and Department of Orthopedic Surgery,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200233,China
Centre for Orthopaedic Research,Medical School,The University of Western Australia,Nedlands,WA 6009,Australia
National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaShanghai Frontiers Science Center of Degeneration and Regeneration in Skeletal System
万方数据
